|Day Low/High||110.91 / 113.31|
|52 Wk Low/High||92.98 / 137.54|
The S&P 500 and Dow Jones Industrial Average trade at session highs early Wednesday afternoon as a broad rally overshadows a slump in health care stocks.
The S&P 500 reverses an earlier loss to post small gains, trading at a new intraday record, thanks to broad gains across all sectors save for health care.
Celgene Corporation (NASDAQ:CELG) today announced that the results of its randomized phase II tnAcity trial of ABRAXANE ® for injectable suspension (paclitaxel protein-bound particles for injectable suspension)...
Celgene Corporation (NASDAQ:CELG), today announced results from two studies (Abstracts #1143, LBA-1) evaluating the investigational use of REVLIMID® (lenalidomide) maintenance therapy in patients with multiple myeloma.
Celgene Corporation (NASDAQ:CELG) today announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE ® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)...
Abstract #905 -- Celgene Corporation (NASDAQ:CELG), today announced results from an analysis of three phase I/II studies evaluating CC-486 in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia...
Acceleron Pharma Inc. (NASDAQ: XLRN) and Celgene Corporation (NASDAQ: CELG) today announced Phase 2 results from an open-label three-month base study and the ongoing long-term safety extension study with luspatercept in...
I spent the weekend with thousands of blood disease researchers. This is what happened.
Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary results from an ongoing investigator initiated Phase 2 study with investigational drug sotatercept in patients with...
While a phase III study progresses, Acceleron is searching for different populations of MDS patients where luspatercept might also be effective.
Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept...
Celgene Corporation (NASDAQ:CELG), Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences today announced the creation of the Myeloma Genome Project, a collaborative initiative aimed at compiling...
Oil prices continued their upward climb Thursday, buoyed by Wednesday's landmark OPEC agreement.
Jim Cramer says he prefers Celgene to Gilead, and Walgreens Boots Alliance to Express Scripts.
Jim Cramer remains a fan of industrials, transports, banks and domestic oil producers.
'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.
Wall Street was torn in two with the energy sector marching the Dow Jones Industrial Average higher, while health care and tech weighed on the Nasdaq.
The Dow Jones Industrial Average leads markets on Wednesday as a rally in crude oil lights a fire under the energy sector.
Stocks turn mixed Wednesday as a rally in crude oil fails to provide an across-the-board lift.
Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.
Doug Kass shares his thoughts on how faster growth won't be easy and how the debt and deficits are out of control.
Cramer shares his views on how much further Citigroup and Goldman Sachs have to run and cautions that you can't wait for everyone to love a stock.
Celgene Corporation (NASDAQ:CELG) today announced that data from nearly 350 abstracts, including more than 150 oral presentations, evaluating Celgene investigational agents and investigational uses of marketed products will...
Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.
Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.
Celgene Corporation (NASDAQ:CELG) plans to webcast an analyst and investor event being held at the American Society of Hematology (ASH) meeting in San Diego on December 4.
Doug Kass shares his thoughts on considering the contrary and shorting the Cisco Kid.
Cramer shares his views on why some still want to buy Bank of America. Wells Fargo, Celgene and Micron are among the stocks discussed.